These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 33574442)

  • 1. Transgenic inhibition of interleukin-6 trans-signaling does not prevent skeletal pathologies in mucolipidosis type II mice.
    Westermann LM; Baranowsky A; Di Lorenzo G; Danyukova T; Soul J; Schwartz JM; Hendrickx G; Amling M; Rose-John S; Garbers C; Schinke T; Pohl S
    Sci Rep; 2021 Feb; 11(1):3556. PubMed ID: 33574442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased bone formation and increased osteoclastogenesis cause bone loss in mucolipidosis II.
    Kollmann K; Pestka JM; Kühn SC; Schöne E; Schweizer M; Karkmann K; Otomo T; Catala-Lehnen P; Failla AV; Marshall RP; Krause M; Santer R; Amling M; Braulke T; Schinke T
    EMBO Mol Med; 2013 Dec; 5(12):1871-86. PubMed ID: 24127423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mannose 6-phosphate-dependent targeting of lysosomal enzymes is required for normal craniofacial and dental development.
    Koehne T; Markmann S; Schweizer M; Muschol N; Friedrich RE; Hagel C; Glatzel M; Kahl-Nieke B; Amling M; Schinke T; Braulke T
    Biochim Biophys Acta; 2016 Sep; 1862(9):1570-80. PubMed ID: 27239697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel mouse model of a patient mucolipidosis II mutation recapitulates disease pathology.
    Paton L; Bitoun E; Kenyon J; Priestman DA; Oliver PL; Edwards B; Platt FM; Davies KE
    J Biol Chem; 2014 Sep; 289(39):26709-26721. PubMed ID: 25107912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct Modes of Balancing Glomerular Cell Proteostasis in Mucolipidosis Type II and III Prevent Proteinuria.
    Sachs W; Sachs M; Krüger E; Zielinski S; Kretz O; Huber TB; Baranowsky A; Westermann LM; Voltolini Velho R; Ludwig NF; Yorgan TA; Di Lorenzo G; Kollmann K; Braulke T; Schwartz IV; Schinke T; Danyukova T; Pohl S; Meyer-Schwesinger C
    J Am Soc Nephrol; 2020 Aug; 31(8):1796-1814. PubMed ID: 32641396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-6 exhibits both
    McGregor NE; Murat M; Elango J; Poulton IJ; Walker EC; Crimeen-Irwin B; Ho PWM; Gooi JH; Martin TJ; Sims NA
    J Biol Chem; 2019 May; 294(19):7850-7863. PubMed ID: 30923130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AAV8-mediated expression of N-acetylglucosamine-1-phosphate transferase attenuates bone loss in a mouse model of mucolipidosis II.
    Ko AR; Jin DK; Cho SY; Park SW; Przybylska M; Yew NS; Cheng SH; Kim JS; Kwak MJ; Kim SJ; Sohn YB
    Mol Genet Metab; 2016 Apr; 117(4):447-55. PubMed ID: 26857995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system.
    De Benedetti F; Rucci N; Del Fattore A; Peruzzi B; Paro R; Longo M; Vivarelli M; Muratori F; Berni S; Ballanti P; Ferrari S; Teti A
    Arthritis Rheum; 2006 Nov; 54(11):3551-63. PubMed ID: 17075861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cathepsin-Mediated Alterations in TGFß-Related Signaling Underlie Disrupted Cartilage and Bone Maturation Associated With Impaired Lysosomal Targeting.
    Flanagan-Steet H; Aarnio M; Kwan B; Guihard P; Petrey A; Haskins M; Blanchard F; Steet R
    J Bone Miner Res; 2016 Mar; 31(3):535-48. PubMed ID: 26404503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ultrastructural analysis of neuronal and non-neuronal lysosomal storage in mucolipidosis type II knock-in mice.
    Schweizer M; Markmann S; Braulke T; Kollmann K
    Ultrastruct Pathol; 2013 Oct; 37(5):366-72. PubMed ID: 24047352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lysosomal dysfunction causes neurodegeneration in mucolipidosis II 'knock-in' mice.
    Kollmann K; Damme M; Markmann S; Morelle W; Schweizer M; Hermans-Borgmeyer I; Röchert AK; Pohl S; Lübke T; Michalski JC; Käkelä R; Walkley SU; Braulke T
    Brain; 2012 Sep; 135(Pt 9):2661-75. PubMed ID: 22961545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective blockade of interleukin-6 trans-signaling improves survival in a murine polymicrobial sepsis model.
    Barkhausen T; Tschernig T; Rosenstiel P; van Griensven M; Vonberg RP; Dorsch M; Mueller-Heine A; Chalaris A; Scheller J; Rose-John S; Seegert D; Krettek C; Waetzig GH
    Crit Care Med; 2011 Jun; 39(6):1407-13. PubMed ID: 21336117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathogenic variants in GNPTAB and GNPTG encoding distinct subunits of GlcNAc-1-phosphotransferase differentially impact bone resorption in patients with mucolipidosis type II and III.
    Di Lorenzo G; Westermann LM; Yorgan TA; Stürznickel J; Ludwig NF; Ammer LS; Baranowsky A; Ahmadi S; Pourbarkhordariesfandabadi E; Breyer SR; Board TN; Foster A; Mercer J; Tylee K; Velho RV; Schweizer M; Renné T; Braulke T; Randon DN; Sperb-Ludwig F; de Camargo Pinto LL; Moreno CA; Cavalcanti DP; Amling M; Kutsche K; Winter D; Muschol NM; Schwartz IVD; Rolvien T; Danyukova T; Schinke T; Pohl S
    Genet Med; 2021 Dec; 23(12):2369-2377. PubMed ID: 34341521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic targeting of interleukin-6 trans-signaling does not affect the outcome of experimental tuberculosis.
    Sodenkamp J; Waetzig GH; Scheller J; Seegert D; Grötzinger J; Rose-John S; Ehlers S; Hölscher C
    Immunobiology; 2012 Oct; 217(10):996-1004. PubMed ID: 22387074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-6 deletion stimulates revascularization and new bone formation following ischemic osteonecrosis in a murine model.
    Kuroyanagi G; Adapala NS; Yamaguchi R; Kamiya N; Deng Z; Aruwajoye O; Kutschke M; Chen E; Jo C; Ren Y; Kim HKW
    Bone; 2018 Nov; 116():221-231. PubMed ID: 30125727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Class A Scavenger Receptor Exacerbates Osteoclastogenesis by an Interleukin-6-Mediated Mechanism through ERK and JNK Signaling Pathways.
    Guo S; Ni Y; Ben J; Xia Y; Zhou T; Wang D; Ni J; Bai H; Wang L; Ma J; Chen Q
    Int J Biol Sci; 2016; 12(10):1155-1167. PubMed ID: 27766031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative pathology of murine mucolipidosis types II and IIIC.
    Vogel P; Payne BJ; Read R; Lee WS; Gelfman CM; Kornfeld S
    Vet Pathol; 2009 Mar; 46(2):313-24. PubMed ID: 19261645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of Lrp5 HBM-causing mutations in Cathepsin-K expressing cells alters bone metabolism.
    Kang KS; Hong JM; Horan DJ; Lim KE; Bullock WA; Bruzzaniti A; Hann S; Warman ML; Robling AG
    Bone; 2019 Mar; 120():166-175. PubMed ID: 30409757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased IL-6 expression in osteoclasts is necessary but not sufficient for the development of Paget's disease of bone.
    Teramachi J; Zhou H; Subler MA; Kitagawa Y; Galson DL; Dempster DW; Windle JJ; Kurihara N; Roodman GD
    J Bone Miner Res; 2014 Jun; 29(6):1456-65. PubMed ID: 24339057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mucolipidosis type II and type III: a systematic review of 843 published cases.
    Dogterom EJ; Wagenmakers MAEM; Wilke M; Demirdas S; Muschol NM; Pohl S; Meijden JCV; Rizopoulos D; Ploeg ATV; Oussoren E
    Genet Med; 2021 Nov; 23(11):2047-2056. PubMed ID: 34172897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.